PDCD1 and neoplasm: Based on the findings described, examination of the LAG-3 expression and co-expression of PD-L1 as well as elucidation of the tumor microenvironment referring to immunotherapeutic resistance to anti-PD-1(L1) were all extremely valuable for adopting suitable immunologic treatment and improving the clinical effect of anti-PD-1(L1) therapy in TNBC.